Free Trial
→ Elon’s “New Gold” (From True Market Insiders) (Ad) Free CTXR Stock Alerts

Citius Pharmaceuticals (CTXR) SEC Filings & 10K Form

Citius Pharmaceuticals logo
$1.80 -0.05 (-2.70%)
Closing price 02/21/2025 04:00 PM Eastern
Extended Trading
$1.80 0.00 (0.00%)
As of 02/21/2025 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare

Recent Citius Pharmaceuticals SEC Filings

Export to Excel
DateFilerForm TypeView
02/14/2025
3:30 PM		Citius Pharmaceuticals (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
02/06/2025
8:20 AM		Citius Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/27/2025
3:05 PM		Citius Pharmaceuticals (Filer)
Form DEF 14A
01/27/2025
3:07 PM		Citius Pharmaceuticals (Filer)
Form DEFA14A
01/16/2025
3:30 PM		Citius Pharmaceuticals (Filer)
Form PRE 14A
01/08/2025
3:05 PM		Citius Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/08/2025
8:00 AM		Citius Pharmaceuticals (Filer)
Form 424B5
01/07/2025
8:11 AM		Citius Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/27/2024
4:10 PM		Citius Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/27/2024
4:00 PM		Citius Pharmaceuticals (Filer)
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
12/20/2024
3:30 PM		Citius Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/27/2024
3:05 PM		Citius Pharmaceuticals (Subject)
Mazur Leonard L (Filed by)
Form SC 13D/A
11/25/2024
4:15 PM		Citius Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/18/2024
3:15 PM		Citius Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/18/2024
7:30 AM		Citius Pharmaceuticals (Filer)
Form 424B5
11/12/2024
4:00 PM		Citius Pharmaceuticals (Issuer)
Holuka Eugene Myron (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/12/2024
4:00 PM		Citius Pharmaceuticals (Issuer)
HOLUBIAK MYRON Z (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/12/2024
4:00 PM		Citius Pharmaceuticals (Issuer)
MCGRATH DENNIS M (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/12/2024
4:00 PM		Citius Pharmaceuticals (Issuer)
Dutia Suren G (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/12/2024
4:00 PM		Citius Pharmaceuticals (Issuer)
Czuczman Myron (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/12/2024
4:00 PM		Citius Pharmaceuticals (Issuer)
Mazur Leonard L (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/12/2024
4:00 PM		Bartushak Jaime (Reporting)
Citius Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
11/12/2024
4:00 PM		Citius Pharmaceuticals (Issuer)
Smith Robert Joseph (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/12/2024
4:00 PM		Citius Pharmaceuticals (Issuer)
Webb Carol (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
09/27/2024
4:25 PM		Citius Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/27/2024
4:26 PM		Citius Pharmaceuticals (Issuer)
Mazur Leonard L (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
09/27/2024
4:27 PM		Citius Pharmaceuticals (Issuer)
HOLUBIAK MYRON Z (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
09/13/2024
7:30 AM		Citius Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/11/2024
4:26 PM		Citius Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/05/2024
3:15 PM		Citius Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/30/2024
3:01 PM		Citius Pharmaceuticals (Issuer)
Webb Carol (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
08/30/2024
3:01 PM		Citius Pharmaceuticals (Issuer)
Holuka Eugene Myron (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
08/16/2024
3:34 PM		CITIUS ONCOLOGY, INC. (Subject)
CITIUS ONCOLOGY, INC. (Subject)
CITIUS ONCOLOGY, INC. (Subject)
CITIUS ONCOLOGY, INC. (Subject)
Citius Pharmaceuticals (Filed by)
Form SC 13D
08/16/2024
3:35 PM		Citius Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/14/2024
5:19 PM		CITIUS ONCOLOGY, INC. (Issuer)
CITIUS ONCOLOGY, INC. (Issuer)
CITIUS ONCOLOGY, INC. (Issuer)
CITIUS ONCOLOGY, INC. (Issuer)
Citius Pharmaceuticals (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
08/14/2024
5:25 PM		CITIUS ONCOLOGY, INC. (Issuer)
CITIUS ONCOLOGY, INC. (Issuer)
CITIUS ONCOLOGY, INC. (Issuer)
CITIUS ONCOLOGY, INC. (Issuer)
Citius Pharmaceuticals (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
08/12/2024
4:10 PM		Citius Pharmaceuticals (Filer)
Form 424B5
08/12/2024
4:25 PM		Citius Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/12/2024
3:51 PM		Citius Pharmaceuticals (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
08/08/2024
8:20 AM		Citius Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/14/2024
3:05 PM		Citius Pharmaceuticals (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
Here’s how you could profit from Elon’s NVIDIA partnership (Ad)

"Elon's #1 AI Stock" SET TO SOAR Forget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful. After all, ChatGPT just works online... While Elon's AI works in the real world.

Get all the details here >>>
05/08/2024
1:22 PM		BlackRock Inc. (Filed by)
Citius Pharmaceuticals (Subject)
Form SC 13G/A
04/30/2024
3:21 PM		Citius Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/13/2024
3:30 PM		Citius Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/03/2024
11:15 PM		Citius Pharmaceuticals (Filer)
Form EFFECT
02/23/2024
3:23 PM		Citius Pharmaceuticals (Filer)
Form S-3
Registration statement under Securities Act of 1933  
02/23/2024
3:18 PM		Citius Pharmaceuticals (Filer)
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
(Data available from 1/1/2016 forward)


Related Companies and Tools

Related Companies
SEC Filings Tools

This page (NASDAQ:CTXR) was last updated on 2/22/2025 by MarketBeat.com Staff
From Our Partners
Secret financial plot unfolding in Washington DC… [DEVELOPING]
What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...
Timothy Sykes | Sponsored
[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIED
Robert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...
NewMarket Health Publishing, LLC. | Sponsored
Buy this AI Stock Before Elon’s Announcement
With Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...
InvestorPlace | Sponsored
Elon’s “New Gold”
MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...
True Market Insiders | Sponsored
Collect $7k per month from Tesla’s SECRET dividend
Tesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...
Investors Alley | Sponsored
What is this southern state hiding?
The financial press had a field day this week after President Donald Trump and Department of Government Effici...
Stansberry Research | Sponsored
Elon Takes Aim at Social Security
Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...
Altimetry | Sponsored
Nvidia’s Next Big Move Comes on Feb. 26
Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...
Weiss Ratings | Sponsored